Teva Pharmaceutical Industries Retained Earnings (Accumulated Deficit) 2010-2024 | TEVA

Teva Pharmaceutical Industries retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-14.519B, a 4.08% increase year-over-year.

  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2023 were $-13.534B, a 4.31% increase from 2022.
  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2022 were $-12.975B, a 23.23% increase from 2021.
  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2021 were $-10.529B, a 3.81% decline from 2020.

Teva Pharmaceutical Industries Retained Earnings (Accumulated Deficit) 2010-2024 | TEVA

  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2023 were $-13.534B, a 4.31% increase from 2022.
  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2022 were $-12.975B, a 23.23% increase from 2021.
  • Teva Pharmaceutical Industries retained earnings (accumulated deficit) for 2021 were $-10.529B, a 3.81% decline from 2020.